Physician profile
Michael Bonner
NPI 1407881501
$1,173.41
in general payments reported to CMS, 2019-2025
14 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $19.33 · 2022: $155 · 2023: $399 · 2024: $66.55 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $342.62 | 2022-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $135.45 | 2019-2025 | Rocklatan, Rhopressa, Clareon |
| Sight Sciences, INC. | $131.04 | 2023 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $121.35 | 2019-2023 | |
| Oyster Point Pharma, INC. | $101.92 | 2022-2023 | Tyrvaya |
| Abbvie INC. | $65.26 | 2022 | |
| Rxsight INC | $64.43 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $45.10 | 2024-2025 | |
| Ethicon US, LLC | $40.92 | 2025 | Surgiflo Hemostatic Matrix, Vistaseal |
| Allergan, INC. | $27.69 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $25.24 | 2023 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.91 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $24.06 | 2024 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $23.42 | 2023 | Eylea |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.